Hostname: page-component-848d4c4894-xfwgj Total loading time: 0 Render date: 2024-07-07T05:47:27.565Z Has data issue: false hasContentIssue false

Association between GRM3 gene polymorphisms and response to treatment in Moroccan schizophrenic patients

Published online by Cambridge University Press:  23 March 2020

H. Lagouaiti
Affiliation:
Faculty of Medicine and Pharmacy, Hassan II University of Casablanca, Laboratory of Clinical Neuroscience and Mental Health, Casablanca, Morocco
G. Zairy
Affiliation:
Faculty of Medicine and Pharmacy, Hassan II University of Casablanca, Laboratory of Clinical Neuroscience and Mental Health, Casablanca, Morocco
H. Charoute
Affiliation:
Institut Pasteur, Human Molecular Genetic Laboratory, Institut Pasteur, Human Molecular Genetic Laboratory, Casablanca, Morocco
R. Somali
Affiliation:
Faculty of Medicine and Pharmacy, Hassan II University of Casablanca, Laboratory of Clinical Neuroscience and Mental Health, Casablanca, Morocco
N. Atouche
Affiliation:
Faculty of Medicine and Pharmacy, Hassan II University of Casablanca, Laboratory of Clinical Neuroscience and Mental Health, Casablanca, Morocco
A. Elalaoui
Affiliation:
Centre National pour la Recherche Scientifique et Technique, Human Molecular Genetic Laboratory, Casablanca, Morocco
O. Battas
Affiliation:
Faculty of Medicine and Pharmacy, Hassan II University of Casablanca, Laboratory of Clinical Neuroscience and Mental Health, Casablanca, Morocco
M. Agoub
Affiliation:
Faculty of Medicine and Pharmacy, Hassan II University of Casablanca, Laboratory of Clinical Neuroscience and Mental Health, Casablanca, Morocco

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Objective

The aim of this study is to evaluate the association between response to treatment in Moroccan schizophrenic patients and GRM3 gene polymorphisms.

Method

We have genotyped three SNPs of GRM3 gene (rs1989796, rs1468412, rs1476455) in 33 Moroccan schizophrenic patients. We assessed the severity of symptoms using Positive and Negative Symptoms Scale (PANSS) and Brief Psychiatric Rating Scale (BPRS) during two months of antipsychotics treatment.

Results

The result revealed a positive change in PANSS negative symptoms in patients with rs1468412SNP and a difference in allele frequency of rs1989796SNP between responders and nonresponders to treatment.

Conclusion

Our data indicate that rs1468412 and rs1989796 GRM3 gene polymorphisms play a role in response to schizophrenia treatment.

Disclosure of interest

The authors have not supplied their declaration of competing interest.

Type
e-Poster Viewing: Schizophrenia and other psychotic disorders
Copyright
Copyright © European Psychiatric Association 2017
Submit a response

Comments

No Comments have been published for this article.